

IMEXPHARM CORPORATION

No.: 03.. /2024/BC-HĐQT-IMP

THE SOCIALIST REPUBLIC OF VIETNAM Independence - Freedom - Happiness

Cao Lanh City, April 5, 2024

REPORT

Re.: Operating expenses of BOD in 2023

Kindly Attn: Esteemed Shareholders of Imexpharm Corporation

- Pursuant to the Law on Enterprises;

- Pursuant to the Charter of Imexpharm Corporation (the "Company").

The Board of Directors ("BOD") respectfully reports to the 2024 Annual General Meeting of Shareholders ("AGM") the operating expenses of the Board of Directors in 2023 and the use of bonuses for extraordinary performance as follows:

Remuneration of the Board of Directors:

No.	Items	Amount (VND)
1	Unused remuneration, bonuses of the BOD from the previous year	2,838,024,220
2	Deducted remuneration and bonuses in 2023	10,790,057,933
2.1	- Deducted remuneration (2% of earning before tax and expenses of BOD)	7,734,447,635
2.2	 Deducted bonuses from 2022 distributed profits 	3,055,610,298
3	Remuneration, bonus paid in 2023	9,253,162,778
4	The unused remuneration, bonuses transferred to 2024	4,374,919,375

Respectfully report to the General Meeting of Shareholders.

Best regards.

ON BEHALE OF THE BOARD OF DIRECTORS Chairwoman (CÔNG T ANH-T. CHUN CHAERHAN

